Adebrelimab (SHR-1316): A Comprehensive Monograph on a Novel PD-L1 Immune Checkpoint Inhibitor

Executive Summary & Drug Profile of Adebrelimab (SHR-1316)

Adebrelimab is a novel, fully humanized immunoglobulin G4 (IgG4) monoclonal antibody that functions as a high-affinity immune checkpoint inhibitor by targeting the programmed death-ligand 1 (PD-L1).[1] Developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd., adebrelimab has achieved a significant clinical milestone with its regulatory approval in China for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) when administered in combination with standard chemotherapy.[4] This approval was predicated on the results of the pivotal Phase 3 CAPSTONE-1 trial, which demonstrated a statistically significant and clinically meaningful improvement in overall survival for this patient population, historically characterized by poor prognosis and limited therapeutic advancement.[7]

The molecular design of adebrelimab is distinguished by specific structural modifications engineered to optimize its therapeutic index. These alterations enhance antibody stability and are intended to minimize off-target immune-related toxicities by ablating effector functions, thereby focusing its activity on the blockade of the PD-1/PD-L1 signaling axis.[2] Beyond its established role in ES-SCLC, adebrelimab is the subject of a broad and ambitious clinical development program investigating its efficacy and safety across a range of other solid tumors. These include non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and gastric cancer, often as a component of innovative combination regimens with chemotherapy, radiotherapy, and other targeted agents.[5] The multiplicity of its development codes and synonyms, such as SHR-1316 and HTI-1088, reflects a typical progression from an internal research compound to a globally recognized therapeutic candidate, with commercial brand names including Arelili® and Ariely® now established in the Chinese market.[5]

Table 1: Adebrelimab Drug Identifiers

Identifier	Details	Source(s)
Generic Name	Adebrelimab	4
DrugBank ID	DB16412	12
CAS Number	2247114-85-6	1
Type	Biotech, Monoclonal Antibody	5
Synonyms/Code Names	SHR-1316, HTI-1088, HTI-1316, Anti-B7-H1, CD274	1
Brand Names (China)	Arelili®, Ariely®	10
Originator	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	5
ATC Code	L01FF05 (WHO)	4
Legal Status	Prescription-only (Rx) in China	4

Molecular Architecture and Differentiated Mechanism of Action

Antibody Class and Structure

Adebrelimab is a fully humanized immunoglobulin G4 kappa (IgG4κ) monoclonal antibody, with a molecular weight of approximately 145.8 kD.[1] The selection of the IgG4 isotype is a deliberate and critical design choice. Unlike the IgG1 isotype, which possesses potent effector functions, IgG4 is naturally associated with significantly lower activity in mediating antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).[6] This structural foundation is central to the therapeutic strategy of adebrelimab.

Target and Binding Mechanism

The therapeutic target of adebrelimab is the programmed death-ligand 1 (PD-L1), a transmembrane protein also known as B7-H1 or CD274.[1] In the tumor microenvironment, cancer cells frequently overexpress PD-L1 to evade immune surveillance. When PD-L1 on a tumor cell binds to its primary receptor, programmed cell death-1 (PD-1), on the surface of activated T-cells, it transmits an inhibitory signal that effectively inactivates the T-cell, preventing it from attacking the cancer cell.[17]

Adebrelimab functions by binding with high specificity and affinity to PD-L1, physically obstructing its interaction with both the PD-1 and B7-1 (CD80) receptors.[2] This blockade effectively "releases the brakes" on the immune system, reversing the T-cell inactivation signal and restoring the capacity of cytotoxic T-lymphocytes (CTLs) to recognize and eliminate PD-L1-expressing tumor cells.[17]

Key Structural Modifications and Their Functional Implications

The molecular architecture of adebrelimab has been meticulously engineered to enhance its therapeutic profile through several key modifications.

• Elimination of Effector Functions: A primary goal in the design of adebrelimab was to create a "purer" checkpoint inhibitor, where the therapeutic benefit arises solely from the blockade of the PD-1/PD-L1 pathway. Since PD-L1 is expressed not only on tumor cells but also on critical immune cells like T-cells and B-cells, an antibody with active effector functions could inadvertently target and destroy these essential immune cells, leading to their depletion and potentially compromising the overall anti-tumor response.[2] To prevent this, adebrelimab was built on an IgG4 backbone, which inherently lacks CDC activity. Furthermore, its Fc region was modified via site-directed mutagenesis (234A/235A) to ablate its affinity for Fcγ receptors, thereby eliminating residual ADCC and antibody-dependent cellular phagocytosis (ADCP) effects.[2] This design ensures that adebrelimab does not cause unintended damage to the patient's immune cells.
• Enhanced Antibody Stability: IgG4 antibodies are naturally susceptible to a process known as Fab-arm exchange (FAE), where half-molecules (one heavy chain and one light chain) can swap with other IgG4 molecules in vivo. This can result in the formation of bispecific antibodies with reduced avidity for their intended target, thereby decreasing efficacy.[2] To overcome this instability, a stabilizing S228P mutation was engineered into the hinge region of adebrelimab. This modification prevents FAE, ensuring that the antibody remains a stable, bivalent molecule that can effectively bind to two PD-L1 targets simultaneously.[2]

The sum of these engineering choices results in a highly optimized therapeutic agent. This molecular design is directly linked to a clinical strategy focused on maximizing the targeted immune response while mitigating the risk of off-target toxicities. Furthermore, preclinical data indicate that adebrelimab possesses a very high binding affinity for PD-L1, with a dissociation constant (Kd​) of approximately 0.27×10−10 nmol/L. This affinity is reported to be stronger than that of other approved PD-L1 inhibitors, such as durvalumab (Kd​ of 6.67×10−10 nmol/L) and atezolizumab (Kd​ of 4.0×10−10 nmol/L).[6] In pharmacology, a lower

Kd​ value signifies tighter binding, which may translate to more potent and sustained target engagement at a given dose, providing a strong biochemical rationale for the robust clinical efficacy observed in pivotal trials.

Comprehensive Pharmacological Profile

Pharmacodynamics

The primary pharmacodynamic effect of adebrelimab is the potentiation of the body's anti-tumor immune response through the blockade of the PD-1/PD-L1 checkpoint.[17] Beyond this core mechanism,

in vitro studies have provided evidence of additional cellular effects. In breast cancer cell lines (SK-BR-3 and AU565), adebrelimab has been shown to inhibit cell proliferation, migration, and invasion. Mechanistically, this was associated with the downregulation of the PI3K/AKT signaling pathway, a key cascade involved in cell growth and survival, and the promotion of apoptosis.[19] These findings suggest that adebrelimab may exert some direct effects on tumor cells that express PD-L1, in addition to its primary role in modulating T-cell function.

Pharmacokinetics

The pharmacokinetic profile of adebrelimab has been characterized through clinical studies, including a comprehensive population pharmacokinetic (PopPK) analysis.

• Absorption and Distribution: Adebrelimab is administered via intravenous infusion. Its drug exposure, as measured by the area under the curve (AUC), increases in a dose-proportional manner across a range of 3–20 mg/kg.[2] It has a volume of distribution at steady state ( Vss​) of approximately 4.35 L, indicating that its distribution is largely confined to the vascular and interstitial compartments, which is typical for monoclonal antibodies.[2]
• Metabolism and Elimination: As a protein, adebrelimab is expected to be metabolized into smaller peptides and amino acids via catabolic pathways. Its systemic clearance is low, at approximately 0.23 L/day.[2] The terminal elimination half-life is approximately 12 to 20 days, which supports an every-3-week dosing interval.[2] Steady state is typically achieved after 12 weeks of repeated dosing, with a modest systemic accumulation ratio of 1.3.[2]
• Population PK Modeling and Dosing Regimen: A sophisticated two-compartment PopPK model was developed using data from 263 patients across two clinical studies.[20] This analysis identified several covariates—including baseline body weight, albumin levels, tumor size, and the presence of anti-drug antibodies (ADAs)—that had a statistically significant impact on drug clearance. However, the magnitude of these effects was not deemed clinically meaningful, and therefore, no dose adjustments are recommended for these patient-specific factors.[20]

This PopPK analysis was instrumental in validating a flat-dosing regimen as an alternative to the initially approved weight-based dose. The modeling demonstrated that a fixed dose of 1200 mg administered every 3 weeks (q3w) results in a distribution of exposure metrics (AUC, Cmax​, and Ctrough​) that is comparable to the 20 mg/kg q3w regimen.[16] The availability of a flat-dosing option carries significant practical advantages in the clinical setting; it simplifies the prescription and administration process, reduces the potential for calculation errors, and can minimize drug wastage, thereby improving convenience and cost-effectiveness for healthcare systems.[21]

An interesting finding from the PopPK analysis was that the decrease in adebrelimab clearance over time was more pronounced in patients who responded to treatment compared to non-responders.[20] This phenomenon can be explained by the concept of target-mediated drug disposition (TMDD). A high tumor burden with extensive PD-L1 expression acts as an "antigen sink," leading to increased drug clearance. As a patient responds to therapy and the tumor shrinks, this antigen sink is reduced, resulting in less TMDD and consequently lower overall drug clearance. This observation provides a quantitative pharmacokinetic reflection of the drug's pharmacodynamic effect on the tumor and may serve as a potential early indicator of therapeutic response.

Clinical Efficacy in Extensive-Stage Small Cell Lung Cancer: A Deep Dive into the CAPSTONE-1 Trial

The cornerstone of adebrelimab's clinical validation is the CAPSTONE-1 trial (NCT03711305), a large-scale, multicenter, randomized, double-blind, placebo-controlled Phase 3 study that established its efficacy and safety as a first-line treatment for ES-SCLC.[8]

Trial Design and Patient Population

The study enrolled 462 treatment-naïve patients with histologically or cytologically confirmed ES-SCLC across 47 tertiary hospitals in China. Eligible patients were between 18 and 75 years of age with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.[8] Patients were randomized on a 1:1 basis to one of two treatment arms:

• Adebrelimab Arm (n=230): Received intravenous adebrelimab (20 mg/kg) in combination with standard chemotherapy consisting of carboplatin (AUC 5 mg/mL/min) and etoposide (100 mg/m²). This induction phase lasted for four to six 21-day cycles. Following induction, patients received maintenance therapy with adebrelimab.[8]
• Placebo Arm (n=232): Received a matching placebo in combination with the same carboplatin and etoposide chemotherapy regimen, followed by placebo maintenance.[8]

Randomization was stratified by key prognostic factors, including the presence of liver metastases, brain metastases, and baseline lactate dehydrogenase (LDH) concentration.[8]

Efficacy Outcomes

The CAPSTONE-1 trial successfully met its primary and key secondary endpoints, demonstrating a clear clinical benefit for the addition of adebrelimab to chemotherapy.

Primary Endpoint: Overall Survival (OS)

The study achieved its primary endpoint, showing a statistically significant and clinically meaningful improvement in OS for patients in the adebrelimab arm.[8]

• Median OS: Was 15.3 months (95% CI, 13.2–17.5) in the adebrelimab group compared to 12.8 months (95% CI, 11.3–13.7) in the placebo group.[7]
• Hazard Ratio (HR): The risk of death was reduced by 28%, with an HR of 0.72 (95% CI, 0.58–0.90; one-sided p=0.0017).[7]
• Landmark Survival Rates: The survival benefit became more pronounced over time. The 2-year OS rate was 31.3% for the adebrelimab arm versus 17.2% for the placebo arm.[25] An updated 3-year analysis showed a doubling of the survival rate, at 21.1% versus 10.5%, respectively.[2]

Secondary Efficacy Endpoints

The addition of adebrelimab also led to improvements in key secondary measures of efficacy.

• Progression-Free Survival (PFS): A statistically significant improvement in PFS was observed. The median PFS was 5.8 months in the adebrelimab arm versus 5.6 months in the placebo arm, with an HR of 0.67 (95% CI, 0.54–0.83; p < 0.0001).[25]
• Objective Response Rate (ORR): The ORR was numerically higher in the adebrelimab group at 70.4%, compared to 65.9% in the placebo group.[24]
• Duration of Response (DoR): Patients treated with adebrelimab experienced more durable responses. The median DoR was 5.6 months versus 4.6 months. Critically, the proportion of patients with an ongoing response at 12 months was five times higher in the adebrelimab arm (19.8% vs. 3.9%).[25]

The efficacy results from CAPSTONE-1 exhibit a pattern characteristic of successful immunotherapy in immunologically "cold" tumors like SCLC. The initial benefit in median PFS is modest, suggesting that the early disease control is primarily driven by the potent chemotherapy backbone in both arms. However, the true value of adebrelimab is revealed in the long-term data. The significant separation in the "tail of the curve" for both PFS (1-year rate of 13.6% vs. 3.1%) and, most importantly, OS (2- and 3-year rates nearly doubled) demonstrates that for a subset of patients, the addition of adebrelimab can convert initial chemotherapy responses into durable, long-term remissions—a benefit not achievable with chemotherapy alone.[25]

Table 2: Summary of Efficacy Outcomes from the CAPSTONE-1 Trial

Endpoint	Adebrelimab + Chemotherapy (n=230)	Placebo + Chemotherapy (n=232)	Hazard Ratio (95% CI) / p-value
Median Overall Survival	15.3 months	12.8 months	HR 0.72 (0.58–0.90); p=0.0017
2-Year OS Rate	31.3%	17.2%	N/A
3-Year OS Rate	21.1%	10.5%	N/A
Median Progression-Free Survival	5.8 months	5.6 months	HR 0.67 (0.54–0.83); p<0.0001
1-Year PFS Rate	13.6%	3.1%	N/A
Objective Response Rate (ORR)	70.4%	65.9%	N/A
Median Duration of Response (DoR)	5.6 months	4.6 months	N/A
Ongoing Response at 12 months	19.8%	3.9%	N/A

Safety, Tolerability, and Risk Management

The safety profile of adebrelimab in combination with chemotherapy was evaluated extensively in the CAPSTONE-1 trial and was found to be acceptable and manageable, with no new or unexpected safety signals identified.[8]

Adverse Events from the CAPSTONE-1 Trial

The overall incidence of high-grade adverse events was driven primarily by the chemotherapy backbone. The rate of Grade 3 or 4 treatment-related adverse events (TRAEs) was nearly identical between the two arms, occurring in 84.8% of patients receiving adebrelimab and 84.1% of those receiving placebo.[25]

• Common High-Grade TRAEs: The most frequently reported Grade 3 or 4 TRAEs were hematological toxicities, consistent with the known profile of carboplatin and etoposide. These included decreased neutrophil count (76% in the adebrelimab arm vs. 75% in the placebo arm), decreased white blood cell count (46% vs. 38%), decreased platelet count (38% vs. 34%), and anemia (28% vs. 28%).[8]
• Serious AEs and Discontinuations: Treatment-related serious adverse events were reported more frequently in the adebrelimab arm (39% vs. 28%).[8] Similarly, discontinuation of any study drug due to TRAEs was slightly higher with adebrelimab (14.8% vs. 6.3%), with discontinuation specifically due to TRAEs from adebrelimab/placebo occurring in 5.2% and 3.9% of patients, respectively.[25] Treatment-related deaths were rare and occurred in two patients (0.9%) in each arm.[8]

Immune-Mediated Adverse Events (irAEs)

As with all PD-1/PD-L1 inhibitors, adebrelimab is associated with a risk of immune-mediated adverse events, which result from generalized immune system activation. In the CAPSTONE-1 trial, irAEs of any grade were more common in patients receiving adebrelimab (27.8%) compared to placebo (17.2%).[25] These events can affect any organ system and may include pneumonitis, colitis, hepatitis, endocrinopathies (such as thyroid disorders and adrenal insufficiency), nephritis, and dermatologic reactions.[29] Prompt recognition and management, often involving corticosteroids, are crucial.

Contraindications and Potential Drug Interactions

While a formal product monograph was not provided in the source materials, contraindications for adebrelimab can be inferred from the exclusion criteria of its pivotal clinical trials. As a class, immune checkpoint inhibitors are generally contraindicated in patients with active or suspected autoimmune diseases, a history of severe hypersensitivity reactions to other monoclonal antibodies, or those requiring systemic immunosuppressive therapy for conditions other than the management of irAEs.[32]

Specific data on drug-drug interactions for adebrelimab are limited. However, as monoclonal antibodies are not metabolized by the cytochrome P450 enzyme system, metabolic drug-drug interactions are not expected.[2] An area of emerging research for the entire class of checkpoint inhibitors is a potential interaction with proton pump inhibitors (PPIs), which have been associated with an increased risk of immune-mediated acute kidney injury in some retrospective studies.[34]

Table 3: Common Grade 3/4 Treatment-Related Adverse Events (CAPSTONE-1)

Adverse Event	Adebrelimab + Chemotherapy (%)	Placebo + Chemotherapy (%)
Decreased Neutrophil Count	76	75
Decreased White Blood Cell Count	46	38
Decreased Platelet Count	38	34
Anemia	28	28
Any Immune-Mediated AE (All Grades)	27.8	17.2
Treatment-Related Serious AEs	39	28
Treatment Discontinuation due to TRAEs	5.2	3.9

Expanding Therapeutic Horizons: Adebrelimab in Other Malignancies and Combinations

The clinical development strategy for adebrelimab extends far beyond its initial approval in ES-SCLC, encompassing a broad program aimed at establishing its role across various solid tumors and in combination with multiple therapeutic modalities.[4] This strategy reflects two central pillars of modern immuno-oncology development: first, combining checkpoint inhibitors with other agents to overcome resistance and enhance efficacy, and second, moving these powerful therapies into earlier stages of disease where the potential for cure is greatest.

Non-Small Cell Lung Cancer (NSCLC)

In NSCLC, adebrelimab is being evaluated in the perioperative (neoadjuvant and adjuvant) setting. A Phase 3 trial (NCT04316364) is currently investigating adebrelimab plus chemotherapy for patients with resectable disease.[14] Promising early data from a Phase 1b trial in this setting revealed a major pathologic response (MPR) rate of 51.4% and a pathologic complete response (pCR) rate of 29.7%, with a manageable safety profile.[38]

Limited-Stage Small Cell Lung Cancer (LS-SCLC)

For patients with LS-SCLC, where the standard of care involves concurrent chemoradiotherapy with curative intent, multiple trials are exploring the integration of adebrelimab. These studies are investigating various combinations and sequences, such as adebrelimab plus apatinib (an anti-VEGFR2 TKI) as adjuvant therapy following chemoradiation (NCT06773156) and adebrelimab combined with chemotherapy and concurrent stereotactic body radiation therapy (SBRT) in the neoadjuvant setting (NCT06562920).[39]

Other Solid Tumors

The development program for adebrelimab includes numerous trials in other malignancies:

• Hepatocellular Carcinoma (HCC): Adebrelimab is being studied in advanced HCC, including in a Phase 1b/2 trial (NCT05924997) that evaluates a triplet combination of adebrelimab (anti-PD-L1), camrelizumab (anti-PD-1), and apatinib (anti-VEGFR2).[5] This approach targets multiple, non-redundant pathways involved in tumor growth and immune evasion.
• Gastroesophageal Cancers: In gastric cancer, a trial (ChiCTR2300077329) is assessing adebrelimab plus apatinib and irinotecan specifically for patients whose disease has become refractory to prior PD-1 inhibitor therapy, addressing a significant unmet need.[5] For resectable esophageal squamous cell carcinoma, a Phase 2 neoadjuvant trial (NCT04215471) is underway.[14]
• Other Malignancies: Further studies are exploring adebrelimab in high-risk locoregionally advanced nasopharyngeal carcinoma (LANPC) combined with chemoradiotherapy (NCT06349889) and as an adjuvant therapy with capecitabine for resected cholangiocarcinoma (NCT06607276).[41]

Table 4: Selected Ongoing Clinical Trials of Adebrelimab

Indication	Trial ID	Phase	Setting	Combination Regimen
Resectable NSCLC	NCT04316364	3	Perioperative	Chemotherapy
Limited-Stage SCLC	NCT06562920	N/A	Neoadjuvant	Chemotherapy + SBRT
Extensive-Stage SCLC	NCT06480864	2	Maintenance	Apatinib
Advanced HCC	NCT05924997	1b/2	First-line	Camrelizumab + Apatinib
High-Risk LANPC	NCT06349889	2	Adjuvant	Chemoradiotherapy
Resected Cholangiocarcinoma	NCT06607276	2	Adjuvant	Capecitabine

Regulatory and Developmental History

Adebrelimab (SHR-1316) is a proprietary molecule developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd., a prominent pharmaceutical company based in China.[5] The development and approval timeline for the drug was notably efficient, reflecting the streamlined regulatory pathways in China for innovative medicines addressing high unmet medical needs.

• October 2018: The pivotal Phase 3 CAPSTONE-1 trial (NCT03711305) was initiated to evaluate adebrelimab as a first-line treatment for ES-SCLC.[43]
• October 29, 2021: Jiangsu Hengrui announced via press release that the CAPSTONE-1 trial had successfully met its primary endpoint of overall survival. The company concurrently announced its intention to seek a pre-New Drug Application meeting with China's National Medical Products Administration (NMPA).[11]
• May 2022: The comprehensive results of the CAPSTONE-1 trial were published in the peer-reviewed journal The Lancet Oncology, providing the international medical community with detailed efficacy and safety data.[8]
• March 14, 2023: The NMPA granted marketing approval to adebrelimab for the first-line treatment of adult patients with ES-SCLC, to be used in combination with carboplatin and etoposide.[4]
• 2023: Following its approval, adebrelimab was incorporated into the Chinese Society of Clinical Oncology (CSCO) clinical practice guidelines for SCLC, receiving a Level 1 recommendation for its approved indication.[2]

The timeline from the initiation of the pivotal Phase 3 trial to regulatory approval spanned just over four years. This rapid progression underscores the effectiveness of China's regulatory reforms, which include priority review pathways designed to accelerate the availability of novel, domestically developed therapies for serious conditions.[46]

Comparative Analysis and Future Perspectives

Positioning within the ES-SCLC Treatment Landscape

Adebrelimab enters a therapeutic landscape for first-line ES-SCLC that has been transformed by the introduction of PD-L1 inhibitors. Its approval places it alongside atezolizumab and durvalumab, which, based on the IMpower133 and CASPIAN trials, respectively, have also established the standard of care as immunotherapy plus chemotherapy.

Indirect Trial Comparisons

In the absence of direct head-to-head trials, several analyses have sought to compare the efficacy of these regimens using indirect methods, such as reconstructing patient-level data from the respective pivotal trials. One such meta-analysis compared data from CAPSTONE-1 (adebrelimab), IMpower133 (atezolizumab), and CASPIAN (durvalumab).[48] The results of this analysis suggested a survival advantage for the adebrelimab regimen, finding that it significantly prolonged OS compared to both atezolizumab (HR 0.76) and durvalumab (HR 0.75). It also demonstrated a reduced risk of disease progression compared to atezolizumab (PFS HR 0.67).[48]

However, these findings must be interpreted with significant caution. A critical appraisal of the underlying trials reveals potential heterogeneity that confounds a direct comparison. Notably, the median OS of the placebo-plus-chemotherapy control arm in the CAPSTONE-1 trial was 12.8 months, which is substantially longer than the control arm outcomes in IMpower133 (10.3 months) and CASPIAN (10.5 months).[49] This discrepancy suggests that the patient population in CAPSTONE-1 may have had a better baseline prognosis or may have received different subsequent lines of therapy that influenced survival. One analysis noted a higher rate of subsequent anti-angiogenic therapy use in the CAPSTONE-1 population, which could be a contributing factor.[50] Therefore, while the indirect evidence is promising for adebrelimab, definitive claims of superiority over atezolizumab or durvalumab cannot be made without a prospective, randomized head-to-head trial.

Table 5: Indirect Comparison of First-Line Immunotherapy Regimens in ES-SCLC

Regimen	Pivotal Trial	Median OS (months)	Median PFS (months)	2-Year OS Rate (%)
Adebrelimab + Chemo	CAPSTONE-1	15.3	5.8	31.3
Atezolizumab + Chemo	IMpower133	12.3	5.2	22.0
Durvalumab + Chemo	CASPIAN	12.9	5.1	22.9
Pembrolizumab + Chemo	KEYNOTE-604	10.8	4.5	22.5

Note: Data are from separate trials and should not be compared directly. Pembrolizumab is not approved for first-line ES-SCLC as the KEYNOTE-604 trial did not meet its primary OS endpoint.

Future Perspectives

The trajectory for adebrelimab points toward continued expansion and integration into the global oncology armamentarium. Key future directions will likely include seeking regulatory approvals in markets outside of China, which will require additional clinical trials in diverse patient populations. The extensive ongoing research program will continue to define its role in other malignancies and in novel combinations, particularly with targeted agents like apatinib that have a strong mechanistic rationale for synergy with immunotherapy. Finally, a critical area of future research will be the identification and validation of predictive biomarkers. While current checkpoint inhibitors in SCLC are used in an unselected population, the ability to identify which patients are most likely to derive the durable, long-term benefit seen in the "tail of the curve" would represent a major advance in personalizing therapy for this aggressive disease. The robust clinical data and differentiated molecular design of adebrelimab position it as a significant and evolving contributor to the field of immuno-oncology.

Works cited

1. Adebrelimab (Anti-B7-H1 / PD-L1 / CD274) - Selleck Chemicals, accessed August 3, 2025, https://www.selleckchem.com/products/adebrelimab-anti-b7-h1-pd-l1-cd274.html
2. Adebrelimab in Small Cell Lung Cancer: From Current Advances to Emerging Combination Strategy and Challenge - PMC, accessed August 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12138384/
3. Progress of research on PD-L1 inhibitor adebrelimab usage in malignant tumors - PubMed, accessed August 3, 2025, https://pubmed.ncbi.nlm.nih.gov/39687879/
4. Adebrelimab - Wikipedia, accessed August 3, 2025, https://en.wikipedia.org/wiki/Adebrelimab
5. Adebrelimab - Drug Targets, Indications, Patents - Patsnap Synapse, accessed August 3, 2025, https://synapse.patsnap.com/drug/78cbea42a153424290e544515e3c539a
6. Progress of research on PD-L1 inhibitor adebrelimab usage in ..., accessed August 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11646850/
7. Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China | BMJ Open, accessed August 3, 2025, https://bmjopen.bmj.com/content/14/4/e077090
8. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - PubMed, accessed August 3, 2025, https://pubmed.ncbi.nlm.nih.gov/35576956/
9. Adebrelimab - Atridia - AdisInsight - Springer, accessed August 3, 2025, https://adisinsight.springer.com/drugs/800049434
10. adebrelimab | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 3, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13085
11. Jiangsu Hengrui Pharmaceuticals Co., Ltd., accessed August 3, 2025, https://www.hengrui.com/en/media/detail-101.html
12. Adebrelimab Recruiting Phase 3 Trials for Non-Small Cell Lung Cancer (NSCLC) Treatment, accessed August 3, 2025, https://go.drugbank.com/drugs/DB16412/clinical_trials?conditions=DBCOND0034130&phase=3&purpose=treatment&status=recruiting
13. Research Grade Adebrelimab - Cell Sciences, accessed August 3, 2025, https://www.cellsciences.com/research-grade-adebrelimab
14. adebrelimab | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 3, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=13085
15. CAS 2247114-85-6 Adebrelimab - BOC Sciences, accessed August 3, 2025, https://www.bocsci.com/product/adebrelimab-cas-2247114-85-6-460687.html
16. Progress of research on PD-L1 inhibitor adebrelimab usage in malignant tumors - Frontiers, accessed August 3, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1468569/pdf
17. Definition of adebrelimab - NCI Drug Dictionary, accessed August 3, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/adebrelimab
18. What is the mechanism of Adebrelimab? - Patsnap Synapse, accessed August 3, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-adebrelimab
19. Adebrelimab (SHR-1316) | Anti-PD-L1 Antibody - MedchemExpress.com, accessed August 3, 2025, https://www.medchemexpress.com/adebrelimab.html
20. Population pharmacokinetics of adebrelimab - Support of alternative flat dose regimen in extensive-stage small-cell lung cancer - PubMed, accessed August 3, 2025, https://pubmed.ncbi.nlm.nih.gov/38711252/
21. Population pharmacokinetics of adebrelimab – Support of alternative flat dose regimen in extensive‐stage small‐cell lung cancer - PubMed Central, accessed August 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11247113/
22. Abstract CT038: Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage SCLC: A phase 3 trial - AACR Journals, accessed August 3, 2025, https://aacrjournals.org/cancerres/article/82/12_Supplement/CT038/701928/Abstract-CT038-Adebrelimab-or-placebo-plus
23. Full article: Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China - Taylor & Francis Online, accessed August 3, 2025, https://www.tandfonline.com/doi/full/10.2147/RMHP.S439119
24. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - ResearchGate, accessed August 3, 2025, https://www.researchgate.net/publication/360582321_Adebrelimab_or_placebo_plus_carboplatin_and_etoposide_as_first-line_treatment_for_extensive-stage_small-cell_lung_cancer_CAPSTONE-1_a_multicentre_randomised_double-blind_placebo-controlled_phase_3_tri
25. Adebrelimab Plus Chemotherapy Meets OS End Point in SCLC, accessed August 3, 2025, https://www.cancernetwork.com/view/adebrelimab-plus-chemotherapy-meets-os-end-point-in-sclc
26. Adebrelimab for the treatment of small-cell lung cancer | BTT - Dove Medical Press, accessed August 3, 2025, https://www.dovepress.com/adebrelimab-in-small-cell-lung-cancer-from-current-advances-to-emergin-peer-reviewed-fulltext-article-BTT
27. Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer. - ASCO Publications, accessed August 3, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.8014
28. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study - PubMed, accessed August 3, 2025, https://pubmed.ncbi.nlm.nih.gov/32468956/
29. Preliminary data of a phase Ib/II trial evaluating the efficacy and safety of adebrelimab, camrelizumab plus apatinib as first-line therapy in patients with advanced hepatocellular carcinoma. - ASCO Publications, accessed August 3, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e16221
30. What is Adebrelimab used for? - Patsnap Synapse, accessed August 3, 2025, https://synapse.patsnap.com/article/what-is-adebrelimab-used-for
31. This label may not be the latest approved by FDA. For current ..., accessed August 3, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf
32. Study Details | The Efficiency of Surgery and Radiotherapy After ..., accessed August 3, 2025, https://clinicaltrials.gov/study/NCT05496166
33. A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients | ClinicalTrials.gov, accessed August 3, 2025, https://clinicaltrials.gov/study/NCT06335355?cond=(neuropathy%20distal%20hereditary%20motor%20autosomal%20recessive)%20OR%20(keap1)&checkSpell=&rank=10
34. Immunological Drug–Drug Interactions Affect the Efficacy and Safety of Immune Checkpoint Inhibitor Therapies - PubMed Central, accessed August 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11256900/
35. Adebrelimab by Jiangsu Hengrui Medicine for Pancreatic Cancer: Likelihood of Approval, accessed August 3, 2025, https://www.pharmaceutical-technology.com/data-insights/adebrelimab-jiangsu-hengrui-medicine-pancreatic-cancer-likelihood-of-approval/
36. Non-Small Cell Lung Cancer (NSCLC; Squamous or Nonsquamous) Recruiting Phase 3 Trials for Adebrelimab (DB16412) | DrugBank Online, accessed August 3, 2025, https://go.drugbank.com/indications/DBCOND0087441/clinical_trials/DB16412?phase=3&status=recruiting
37. Study Details | A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC | ClinicalTrials.gov, accessed August 3, 2025, https://www.clinicaltrials.gov/study/NCT04316364
38. Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial - PubMed, accessed August 3, 2025, https://pubmed.ncbi.nlm.nih.gov/36191882/
39. Adebrelimab Enrolling by Invitation Phase 2 Trials for Limited-stage Small Cell Lung Cancer (LS-SCLC) Treatment - DrugBank, accessed August 3, 2025, https://go.drugbank.com/drugs/DB16412/clinical_trials?conditions=DBCOND0161166&phase=2&purpose=treatment&status=enrolling_by_invitation
40. Study Details | Adebrelimab Combined With Chemotherapy and ..., accessed August 3, 2025, https://clinicaltrials.gov/study/NCT06562920
41. Study Details | Adebrelimab and Chemoradiotherapy in High-risk ..., accessed August 3, 2025, https://clinicaltrials.gov/study/NCT06349889
42. A phase 2, randomized, multicenter study of adjuvant adebrelimab plus capecitabine in resected cholangiocarcinoma with high-risk factors: ACHIEVE. | Journal of Clinical Oncology - ASCO Publications, accessed August 3, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS4220
43. Study Details | Study of Carboplatin Plus Etoposide With or Without ..., accessed August 3, 2025, https://clinicaltrials.gov/study/NCT03711305
44. Adebrelimab (SHR-1316) | CAS 2247114-85-6 - AbMole BioScience, accessed August 3, 2025, https://www.abmole.com/products/adebrelimab.html
45. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1) - larvol clin, accessed August 3, 2025, https://clin.larvol.com/article-detail/57071262
46. China Regulatory Reform: An Update on Review Timelines and Drug Lag - PPD, accessed August 3, 2025, https://www.ppd.com/wp-content/uploads/2020/03/Regulatory-Focus-2018.05-China.pdf
47. China's Evolving Regulatory Environment: Special Report - PPD, accessed August 3, 2025, https://www.ppd.com/wp-content/uploads/2020/07/Regulatory-Focus-2020.01.pdf
48. The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data - Frontiers, accessed August 3, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1185577/full
49. The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data - PubMed Central, accessed August 3, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10196127/
50. (PDF) The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data - ResearchGate, accessed August 3, 2025, https://www.researchgate.net/publication/370951777_The_efficacy_of_adebrelimab_compared_with_durvalumab_and_atezolizumab_in_untreated_extensive-stage_small-cell_lung_cancer_a_survival_analysis_of_reconstructed_patient-level_data